Revefenacin

Drug Profile

Revefenacin

Alternative Names: GSK 1160724; TD-4208

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Antiasthmatics
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Jul 2017 Theravance announces intention to submit NDA to US FDA in the fourth quarter of 2017
  • 19 Jul 2017 Adverse events data from a phase III trial in Chronic obstructive pulmonary disease released by Theravance Biopharma
  • 01 Jun 2017 Theravance Biopharma completes a phase III trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02518139)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top